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Edited by Barry HalliwellAbstract The clinically established gold-based antiarthritic
drug auranoﬁn (AF) manifests a pronounced reactivity toward
thiol and selenol groups of proteins. In particular, AF behaves
as a potent inhibitor of mammalian thioredoxin reductases caus-
ing severe intracellular oxidative stress. Given the high sensitiv-
ity of Plasmodium falciparum to oxidative stress, we thought
that auranoﬁn might act as an eﬀective antimalarial agent. Thus,
we report here new experimental results showing that auranoﬁn
and a few related gold complexes strongly inhibit P. falciparum
growth in vitro. The observed antiplasmodial eﬀects probably
arise from direct inhibition of P. falciparum thioredoxin reduc-
tase. The above ﬁndings and the safe toxicity proﬁle of auranoﬁn
warrant rapid evaluation of AF for malaria treatment in animal
models.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Since the 1930s, a number of injectable gold(I) thiolates
drugs, in particular myochrysine, sanochrysine, allochrysine,
and solganol [1,2]. have been widely employed in the clinics
for the treatment of rheumatoid arthritis (the so called Chryso-
therapy). Later on, in 1979, a new antiarthritic gold(I)
phosphine compound, ((2,3,4,6-tetra-O-acetyl-1-(thio-kS)-b-D-
glucopyranosato)(triethylphosphine) gold(I)), auranoﬁn (AF),
(Fig. 1) was introduced in the clinics, with the signiﬁcant advan-
tage of an oral administration [3]. Today, chrysotherapy still
represents an eﬀective option for the treatment of severe forms
of rheumatoid arthritis though it is being progressively replaced
by new and more sophisticated therapeutic approaches.
In spite of their long and established clinical use, the mech-
anism of action of antiarthritic gold drugs is still largely*Corresponding author. Fax: +39 0 55 457 3385.
E-mail address: luigi.messori@uniﬁ.it (L. Messori).
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doi:10.1016/j.febslet.2008.02.028controversial. However, recent studies point out that antiar-
thritic gold drugs directly interfere with the functioning of
the immune system, at various levels [4,5]. In addition, a num-
ber of biochemical studies revealed that gold drugs behave as
potent ‘‘thiol reactive species’’ and act as eﬀective inhibitors
of a number of proteases (mostly cysteine proteases) [6,7], in-
volved in the progression of rheumatoid arthritis (RA). It also
emerged that auranoﬁn and some related gold drugs are strong
inhibitors of mammalian thioredoxin reductases (TrxR), both
in the cytosol and in the mitochondria [8–10]. Notably, thiore-
doxin reductase inhibition is associated with important modi-
ﬁcations of the intracellular redox balance and, in particular,
with induction of severe oxidative stress and relevant cytotoxic
eﬀects in vitro [11,12].2. Auranoﬁn: a possible antimalarial agent?
This latter feature of AF, i.e. its ability to act as a strong
inhibitor of thioredoxin reductase (in the nM range), suggests
that AF might display additional pharmacological uses beyond
RA therapy. Indeed, thioredoxin reductases are emerging in
the last years as an important class of likely drug targets for
a variety of diseases [13]. Various research groups formerly
analyzed the possible use of auranoﬁn and related gold(I) com-
plexes as cytotoxic and anticancer drugs. We explore here
whether AF may manifest any signiﬁcant antiplasmodial eﬀect
and thus be of potential interest for malaria treatment.
Malaria is today a major health emergency on the interna-
tional scale and also a real challenge for modern pharmacol-
ogy [14]. Owing to the frequent appearance of drug-resistant
Plasmodium strains, the classical antimalarial drugs tend to be-
come rapidly obsolete, generating a continuous need for new
therapeutic agents, possibly endowed with innovative mecha-
nisms of action. Remarkably, Plasmodium falciparum is known
to be particularly sensitive and vulnerable to oxidative stress;
in particular, P. falciparum thioredoxin reductase has been val-
idated as a ‘‘druggable’’ target for the development of new
antimalarials [15]. As P. falciparum thioredoxin reductase
bears a number of functionally relevant cysteines (but no sele-
nol groups) [16], we thought that thiol-reactive gold drugsblished by Elsevier B.V. All rights reserved.
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Fig. 2. Antiplasmodial activities of gold compounds. Percentages of
inhibition of 3D7 P. falciparum strain growth against increasing
concentrations of auranoﬁn, Au(PEt3)Cl, aurothiomalate and AuCy-
clam, respectively. The data are expressed assuming no inhibition for
untreated controls.
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Fig. 1. Chemical structures of the selected gold complexes.
Table 1
IC50 values for auranoﬁn, Au(PEt3)Cl, aurothiomalate, AuCyclam,
artemisinin (ART), ART/50 nM Auranoﬁn and ART/100 nM auran-
oﬁn against 3D7 P. falciparum strain
Name of compounds 3D7 P. falciparum strain IC50 (95% CI)
A.R. Sannella et al. / FEBS Letters 582 (2008) 844–847 845might display appreciable antiplasmodial actions, through a
direct and potent inhibition of this enzyme. These observations
prompted us to measure the eﬀects of a few representative gold
drugs on P. falciparum growth in vitro. To our surprise, despite
a certain number of metal complexes, and even gold com-
pounds, had earlier been tested as antimalarial agents [17],
we realized that classical antiarthritic gold drugs, to the best
of our knowledge, had never been considered for this scope.
Auranoﬁn 142 nM (132–152)
Au(PEt3)Cl 2.1 lM (2.0–2.2)
Aurothiomalate 168 lM (160–170)
AuCyclam 439 lM (428–440)
Artemisinin (ART) 16 nM (14.9–17.3)
ART/50 nM auranoﬁn 12 nM* (8.9–12.3)
ART/100 nM auranoﬁn 9 nM* (7–13)
*P < 0.001.3. Direct evidence that auranoﬁn and a few related gold
compounds strongly inhibit P. falciparum growth
The antimalarial eﬀects of auranoﬁn were assayed in vitro
through a validated experimental procedure based on the
determination of P. falciparum lactate dehydrogenase (pLDH)
activity (see Supporting Information Available for details).
Measuring pLDH provides indeed a selective and easy screen-
ing method for the identiﬁcation and quantitation of parasite
growth in in vitro cultures [18]. For comparison purposes the
eﬀects of three additional and structurally diverse gold
compounds, namely gold(I) triethylphosphine chloride
(Au(PEt3)Cl), sodium aurothiomalate and gold(III) cyclam
(AuCyclam), reported in Fig. 1, were measured as well.
Au(PEt3)Cl is a derivative of auranoﬁn where the thioglucose
ligand is replaced by a chloride ion; aurothiomalate is the anti-
arthritic gold(I) drug myocrysine; at variance, AuCyclam is a
gold(III) compound where the gold center is tightly coordi-
nated to four nitrogens, within a roughly square planar
arrangement [19]. Such a strong coordination environment
reasonably results into a marked decrease of reactivity.
Results of P. falciparum growth assays, in the presence of the
various gold compounds, are shown in Fig. 2, while Table 1
summarizes the concentrations inhibiting the cell viability by
50% (IC50) determined for each species. It is evident that
auranoﬁn, even at very low concentrations, causes a strong
and nearly complete inhibition of P. falciparum growth, with
an IC50 value of 142 nM; Au(PEt3)Cl shows a similar trend
but with a signiﬁcantly higher IC50 value of. 2.1 lM. In con-
trast, aurothiomalate and AuCyclam are far less eﬀective; theirIC50 values being 168 lM and 439 lM, respectively (Table 1).
It is of interest to observe that all gold compounds, starting
from the lowest tested concentrations, cause a partial and
rather constant inhibition of P. falciparum growth (10–
25%); this observation implies, most likely, the coexistence of
two independent cytotoxic pathways, one of which is saturated
very soon. This peculiar behavior clearly emerges from inspec-
tion of the recorded P. falciparum growth inhibition proﬁles;
characteristic proﬁles obtained in the case of AF and
Au(PEt3)Cl are reported in Fig. 3.
In our opinion, the above reported results are of great inter-
est since a very important antiplasmodial activity is described
for the ﬁrst time for the antiarthritic gold(I) drug auranoﬁn.
This ﬁnding might imply that our working hypothesis is basi-
cally correct as the known and relevant inhibitory eﬀects of AF
toward thioredoxin reductase [9,10] are apparently reﬂected
into a strong inhibition of P. falciparum growth.
Of course, further work is needed to conﬁrm the validity of
such hypothesis. In particular, speciﬁc studies on the inhibition
of P. falciparum thioredoxin reductase by auranoﬁn and
related gold drugs would be warranted. In any case, if the
relevant antiplasmodial eﬀects that we have observed here
in vitro, will be conﬁrmed by the animal studies that we are
planning, the way would be open for the rapid clinical testing
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Fig. 3. Percentage of 3D7 P. falciparum growth as a function of the
concentration (M) of auranoﬁn or Au(PEt3)Cl.
846 A.R. Sannella et al. / FEBS Letters 582 (2008) 844–847of auranoﬁn in malaria treatment. Indeed, AF is already in the
clinics since more than 25 years and presents a well known and
quite safe toxicity proﬁle: thus, its clinical use for a diﬀerent
therapeutic indication might be aﬀorded very quickly and
straightforwardly. Also, it is worthwhile reminding that AF
is taken up very eﬃciently by erythrocytes [20], one of the ma-
jor sites where a strong antiplasmodial action is required; this
additional feature might render its in vivo antimalarial actions
even more eﬀective.4. The combined eﬀects of artemsinin and auranoﬁn
Since we hypothesize that the speciﬁc antiproliferative eﬀects
of AF toward P. falciparum probably arise from induction of
oxidative stress, we decided to measure its antiplasmodial
eﬀects in combination with artemisinin. Artemisinin (ART),Fic of ART
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Fig. 4. Isobolograms showing the interaction between ART and
auranoﬁn when administered on 3D7 P. falciparum strain. ART was
given at non-cytotoxic doses, ranging from 0.625 nM to 40 nM, in the
presence of 0, 50 or 100 nM auranoﬁn. Fic is the fractional inhibitory
concentration.today one of the most potent antimalarial agents available in
the clinics (with an IC50 value falling in the very low nano-
molar range); is thought to work through induction of intracel-
lular oxidative stress [21,22]. Thus, we wondered whether these
two drugs, i.e. artemisinin and auranoﬁn might manifest any
signiﬁcant synergism. Their possible interactions were evalu-
ated through an established methodology relying on the so
called ‘‘isobolograﬁc’’ analysis [23,24]. Using AF, either 50
or 100 nM, in combination with artemisinin, the sum of FICs
was 1.2 and 1.03, respectively, when administered on 3D7
P. falciparum strain. The results of isobolograﬁc analysis are
thus consistent with an additive eﬀect of both auranoﬁn
concentrations, as shown in Fig. 4; any antagonism between
these two agents may be ruled out.5. Concluding remarks and perspectives
In conclusion, based on a simple mechanistic hypothesis and
a few selective P. falciparum growth inhibition measurements
in vitro, we have demonstrated for the ﬁrst time that the anti-
arthritic drug AF displays very pronounced antiplasmodial ef-
fects, and thus merits further investigations as a potential
antimalarial drug. Moreover, we have shown, through isobo-
lograﬁc analysis, that AF displays additive antimalarial eﬀects
when given in combination with artemisinin. Signiﬁcant but
less potent antiplasmodial eﬀects have been measured for the
other investigated gold compounds.
The observed antiplasmodial eﬀects are probably mediated
by severe oxidative stress originating from P. falciparum thio-
redoxin reductase inhibition. Of course, further experimental
work is absolutely warranted to support this latter statement;
however the presence of a few functionally relevant cysteine
residues at the active site of P. falciparum TrxR makes us con-
ﬁdent that our working hypothesis is well grounded. If the
eﬀectiveness of antimalarial drug discovery strategies based
on direct inhibition of thioredoxin reductase by metallic com-
pounds will be eventually proved for AF, the way is open to
the extensive testing of several other thiol reactivemetallodrugs
showing acceptable toxicity requirements.
Finally, we like to stress further that AF is in clinical use
since more than 20 years. Looking for new uses of old (and
thus clinically established) drugs represents today a very prom-
ising and eﬀective strategy of modern drug discovery with
obvious advantages. Indeed, much work concerning the safety
proﬁle can be avoided leading to a drastic reduction of times
and costs. New therapeutic applications for some established
drugs have been identiﬁed in the last years; a few relevant cases
are described in the recent literature [25,26]. Auranoﬁn might
hopefully represent another successful example for this kind
of strategy.
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